Literature DB >> 16033093

P53 expression in vulvar carcinoma, vulvar intraepithelial neoplasia, squamous cell hyperplasia and lichen sclerosus.

Peer Hantschmann1, Sonja Sterzer, Udo Jeschke, Klaus Friese.   

Abstract

BACKGROUND: p53 inactivation due to oncogenic viral proteins or mutations is an important molecular mechanism in carcinogenesis, which has also been demonstrated for vulvar carcinoma. To evaluate p53 changes in vulvar carcinogenesis, we analyzed p53 expression in vulvar carcinoma, vulvar intraepithelial neoplasia (VIN), lichen sclerosus (LS) and squamous cell hyperplasia (SH). PATIENTS AND METHODS: Seventy-three carcinomas, 141 cases of VIN, 55 biopsies of LS with 8 associated to carcinoma, 57 cases of SH with 14 associated to carcinoma and 10 cases without neoplastic changes were stained immunohistologically for p53. The pattern, intensity and number of stained cells were analyzed. Results were compared to p53 expression in vulvar epithelium without neoplastic changes and analyzed statistically by chi2-test.
RESULTS: Normal vulvar epithelium showed low p53 staining in the basal epithelial layers. Forty % of LS and SH not associated to carcinoma showed immunohistological signs of p53 mutation, while cases associated with carcinoma did so in 90%. In VIN, p53 was predominantly overexpressed in the differentiated subtype. Sixty-seven % of the carcinomas showed immunohistological changes of p53 expression. Tumors with low p53 expression were significantly associated with patients younger than 50 years (p<0.01) and basaloid or condylomatous tumor type (p<0.015). There were three different patterns of p53 staining, which were significantly correlated with tumor type (p<0.01).
CONCLUSION: p53 mutations are present in typical keratinizing carcinomas, precursor lesions and disorders with elevated risk for vulvar cancer. Thus, p53 mutation seems to occur early in vulvar carcinogenesis and may become a useful marker, especially in lesions with increased risk of carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16033093

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

1.  Expression of galectin-7 in vulvar lichen sclerosus and its effect on dermal fibroblasts.

Authors:  Yi Zhao; Shanshan Zhao; Hui Li; Xin Qin; Xin Wu
Journal:  Oncol Lett       Date:  2018-06-04       Impact factor: 2.967

Review 2.  [HPV-associated alterations of the vulva and vagina. Morphology and molecular pathology].

Authors:  L-C Horn; K Klostermann; S Hautmann; A K Höhn; M W Beckmann; G Mehlhorn
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

3.  Aberrant staining patterns of E-cadherin and β-catenin: a potential diagnostic value for distinguishing vulvar intraepithelial neoplasia from non-neoplastic vulvar lesions.

Authors:  Bo Li; Qingfu Zhang; Ling Ouyang; Lin Jia; Xue Han; Yang Zhou; Xin Tong; Zixuan Song; Shulang Zhang; Xueshan Qiu
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

Review 4.  The Immunogenetics of Morphea and Lichen Sclerosus.

Authors:  Pooya Khan Mohammad Beigi
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  [Pathoanatomical preparation and reporting of specimens from precancerous lesions and carcinomas of the vulva].

Authors:  L-C Horn; K Schierle; K Klostermann; H-G Schnürch; P Hantschmann
Journal:  Pathologe       Date:  2009-02       Impact factor: 1.011

Review 6.  Squamous precursor lesions of the vulva: current classification and diagnostic challenges.

Authors:  Lien N Hoang; Kay J Park; Robert A Soslow; Rajmohan Murali
Journal:  Pathology       Date:  2016-04-23       Impact factor: 5.306

7.  Therapeutic comparison between treatments for Vulvar Lichen Sclerosus: study protocol of a randomized prospective and controlled trial.

Authors:  Renata A Belotto; Maria Cristina Chavantes; João Paulo Tardivo; Roberto Euzébio Dos Santos; Raquel Civolani Marques Fernandes; Anna Carolina Ratto Tempestini Horliana; Christiane Pavani; Daniela Fátima Teixeira da Silva
Journal:  BMC Womens Health       Date:  2017-08-10       Impact factor: 2.809

8.  Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro.

Authors:  Zhihui Wang; Mette S Førsund; Claes G Trope; Jahn M Nesland; Ruth Holm; Ana Slipicevic
Journal:  Cancer Med       Date:  2018-07-02       Impact factor: 4.452

9.  Differentiated vulvar intraepithelial neoplasia (dVIN): the most helpful histological features and the utility of cytokeratins 13 and 17.

Authors:  Shatavisha Dasgupta; Patricia C Ewing-Graham; Folkert J van Kemenade; Helena C van Doorn; Vincent Noordhoek Hegt; Senada Koljenović
Journal:  Virchows Arch       Date:  2018-09-06       Impact factor: 4.064

10.  MicroRNA‑4712‑5p promotes proliferation of the vulvar squamous cell carcinoma cell line A431 by targeting PTEN through the AKT/cyclin D1 signaling pathways.

Authors:  Shaojie Yang; Yanyan Zhao; Lufang Wang; Chang Liu; Ye Lu; Zhidong Fang; Hongshuang Shi; Wenyi Zhang; Xin Wu
Journal:  Oncol Rep       Date:  2019-09-17       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.